All In Biotech

Drug Trial Radar · NCT04233879

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 599 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

599

Actual

Start

Feb 28, 2020

Primary completion

Nov 17, 2022

Study completion Jan 29, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL \[also known as MK-8591A\]) in treatment-naïve participants living with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.

Conditions

  • HIV-1 Infection

Interventions

  • DOR/ISLDrug

    100 mg DOR/0.75 mg ISL FDC single tablet taken once daily by mouth.

  • BIC/FTC/TAFDrug

    BIC/FTC/TAF 50/200/25 mg FDC single tablet taken once daily by mouth.

  • Placebo to BIC/FTC/TAFDrug

    Placebo single tablet matched to BIC/FTC/TAF taken by mouth.

  • Placebo to DOR/ISLDrug

    Placebo single tablet matched to DOR/ISL taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48Time frame: Week 48
  2. Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48Time frame: Up to approximately 48 weeks
  3. Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48Time frame: Up to approximately 48 weeks

Locations

95 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)

    Birmingham, Alabama

  • Pueblo Family Physicians ( Site 5606)

    Phoenix, Arizona

  • Ruane Clinical Research Group, Inc. ( Site 5624)

    Los Angeles, California

  • Midway Immunology and Research ( Site 5622)

    Ft. Pierce, Florida

  • The Kinder Medical Group ( Site 5615)

    Miami, Florida

  • Floridian Clinical Research, LLC ( Site 5625)

    Miami Lakes, Florida

  • Orlando Immunology Center ( Site 5613)

    Orlando, Florida

  • CAN Community Health ( Site 5627)

    Sarasota, Florida

  • Triple O Research Institute, P.A. ( Site 5621)

    West Palm Beach, Florida

  • Columbus Regional Research Institute ( Site 5616)

    Columbus, Georgia

  • Infectious Disease Specialists Of Atlanta PC ( Site 5608)

    Decatur, Georgia

  • Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633)

    Minneapolis, Minnesota

  • Kansas City CARE Clinic ( Site 5607)

    Kansas City, Missouri

  • University of Pennsylvania ( Site 5630)

    Philadelphia, Pennsylvania

  • Saint Hope Foundation, Inc. ( Site 5629)

    Bellaire, Texas

  • North Texas ID Consultants, PA ( Site 5604)

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates P.A. ( Site 5619)

    Fort Worth, Texas

  • Instituto Oulton ( Site 5804)

    Córdoba, Argentina

  • Helios Salud S.A. ( Site 5802)

    Buenos Aires, Buenos Aires F.D., Argentina

  • IDEAA Foundation ( Site 5807)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Fundación Huesped ( Site 5801)

    C.a.b.a, Buenos Aires F.D., Argentina

  • Instituto CAICI ( Site 5803)

    Rosario, Santa Fe Province, Argentina

  • Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 5703)

    Hamilton, Ontario, Canada

  • Toronto General Hospital - University Health Network ( Site 5705)

    Toronto, Ontario, Canada

  • Clinique Medicale L Actuel ( Site 5714)

    Montreal, Quebec, Canada

  • McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 5702)

    Montreal, Quebec, Canada

  • Hospital Dr. Hernan Henriquez Aravena ( Site 5905)

    Temuco, Araucania, Chile

  • Clinica Universidad Catolica del Maule ( Site 5909)

    Talca, Maule Region, Chile

  • Clinica Arauco Salud ( Site 5900)

    Santiago, Region M. de Santiago, Chile

  • Hospital Clinico de la Universidad Catolica ( Site 5903)

    Santiago, Region M. de Santiago, Chile

  • Fundacion Arriaran ( Site 5901)

    Santiago, Region M. de Santiago, Chile

  • Centro Cardiovascular Cardiosur ( Site 5907)

    Santiago, Region M. de Santiago, Chile

  • Hospital Universitario San Ignacio ( Site 6005)

    Bogotá, Bogota D.C., Colombia

  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 6006)

    Bogotá, Bogota D.C., Colombia

  • Fundacion Valle del Lili ( Site 6001)

    Cali, Valle del Cauca Department, Colombia

  • A.P.H. Paris, Hopital Saint Louis ( Site 6114)

    Paris, France

  • Hopital Saint-Antoine ( Site 6113)

    Paris, France

  • Hopital Pitie Salpetriere ( Site 6111)

    Paris, France

  • A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 6124)

    Paris, Ain, France

  • Hopital de la Croix-Rousse ( Site 6127)

    Lyon, Auvergne-Rhône-Alpes, France

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.